2-(2-(naphthalene-1-yl)ethoxy)ethanol | 227808-10-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(2-(naphthalene-1-yl)ethoxy)ethanol
• 英文别名: 2-(2-naphthalen-1-yl-ethoxy)-ethanol；2-(2-naphthalen-1-ylethoxy)ethanol
• CAS: 227808-10-8
• 化学式: C₁₄H₁₆O₂
• 分子量: 216.28
• InChiKey: FJQWBYPTPIUONC-UHFFFAOYSA-N

物化性质

• 沸点：
  375.2±17.0 °C(Predicted)
• 密度：
  1.119±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2-(naphthalene-1-yl)ethoxy)ethanol 在 sodium hydride 、 三乙胺 、 sodium iodide 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 7.0h， 生成 N,N-dimethyl-3-(3-(3-(2-(2-(naphthalene-1-yl)ethoxy)ethoxy)prop-1-yn-1-yl)-10,11-dihydro-5H-dibenzo[b,f]azepine-5-yl)propane-1-amine
  参考文献：
  名称：

  Synthesis and inhibitory evaluation of 3-linked imipramines for the exploration of the S2 site of the human serotonin transporter

  摘要：

  The human serotonin transporter is the primary target of several antidepressant drugs, and the importance of a primary, high affinity binding site (S1) for antidepressant binding is well documented. The existence of a lower affinity, secondary binding site (S2) has, however, been debated. Herein we report the synthesis of 3-position coupled imipramine ligands from clomipramine using a copper free Sonogashira reaction. Ligand design was inspired by results from docking and steered molecular dynamics simulations, and the ligands were utilized in a structure-activity relationship study of the positional relationship between the S1 and S2 sites. The computer simulations suggested that the S2 site does indeed exist although with lower affinity for imipramine than observed within the S1 site. Additionally, it was possible to dock the 3-linked imipramine analogs into positions which occupy the S1 and the S2 site simultaneously. The structure activity relationship study showed that the shortest ligands were the most potent, and mutations enlarging the proposed S2 site were found to affect the larger ligands positively, while the smaller ligands were mostly unaffected. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.04.039
• 作为产物：
  描述：

  1-萘乙醇 在 dimethyl sulfide borane 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.17h， 生成 2-(2-(naphthalene-1-yl)ethoxy)ethanol
  参考文献：
  名称：

  Synthesis and inhibitory evaluation of 3-linked imipramines for the exploration of the S2 site of the human serotonin transporter

  摘要：

  The human serotonin transporter is the primary target of several antidepressant drugs, and the importance of a primary, high affinity binding site (S1) for antidepressant binding is well documented. The existence of a lower affinity, secondary binding site (S2) has, however, been debated. Herein we report the synthesis of 3-position coupled imipramine ligands from clomipramine using a copper free Sonogashira reaction. Ligand design was inspired by results from docking and steered molecular dynamics simulations, and the ligands were utilized in a structure-activity relationship study of the positional relationship between the S1 and S2 sites. The computer simulations suggested that the S2 site does indeed exist although with lower affinity for imipramine than observed within the S1 site. Additionally, it was possible to dock the 3-linked imipramine analogs into positions which occupy the S1 and the S2 site simultaneously. The structure activity relationship study showed that the shortest ligands were the most potent, and mutations enlarging the proposed S2 site were found to affect the larger ligands positively, while the smaller ligands were mostly unaffected. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.04.039

文献信息

• PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：MIURA Tomoya

  公开号：US20130085132A1

  公开（公告）日：2013-04-04

  The present invention provides a pyrazole compound of the following general Formula [Ib] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use: wherein each symbol is the same as defined in the description.

  本发明提供了一种具有SGLT1抑制活性的下式[Ib]所示的吡唑化合物、或其药物可接受的盐、包含该化合物的药物组合物及其医药用途： 其中每个符号如说明书中所定义。
• 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists
  申请人：Bailey Andrew

  公开号：US20090221653A1

  公开（公告）日：2009-09-03

  The present invention provides compounds of formula (I) wherein the variables are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）化合物，其中变量如规范中定义，其制备过程，包含它们的制药组合物以及它们在治疗中的使用。
• PYRAZOLE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：Japan Tobacco, Inc.

  公开号：EP2784074A1

  公开（公告）日：2014-10-01

  A compound of the following general Formula [Ib]: , wherein each symbol is the same as defined in the description; or a pharmaceutically acceptable salt thereof.

  以下通式[Ib]的化合物： 其中各符号与描述中定义的相同；或其药学上可接受的盐。
• WO2007/27134
  申请人：——

  公开号：——

  公开（公告）日：——
• US8846746B2
  申请人：——

  公开号：US8846746B2

  公开（公告）日：2014-09-30